Becton, Dickinson and Company (BDX)
(Delayed Data from NYSE)
$237.84 USD
+0.54 (0.23%)
Updated Jul 29, 2024 04:00 PM ET
After-Market: $237.77 -0.07 (-0.03%) 7:58 PM ET
2-Buy of 5 2
B Value D Growth F Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
BDX 237.84 +0.54(0.23%)
Will BDX be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for BDX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BDX
Sustained Product Demand Likely to Aid BD's (BDX) Q3 Earnings
Countdown to Becton Dickinson (BDX) Q3 Earnings: A Look at Estimates Beyond Revenue and EPS
BDX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Reasons to Retain DENTSPLY SIRONA (XRAY) in Your Portfolio Now
Veeva Systems' (VEEV) Vault EDC to Boost Vita Global's Workflow
Reasons to Add The Cooper Companies (COO) to Your Portfolio Now
Other News for BDX
Key Takeaways From Becton Dickinson Analyst Ratings
Becton Dickinson price target raised by $10 at Stifel, here's why
Becton, Dickinson (BDX) Shares Cross Above 200 DMA
Becton Dickinson, Quest Diagnostics enter collaboration agreement
BD, Quest Diagnostics Join Forces to Develop Companion Diagnostics for Cancer, Other Diseases